Corrects Q4 EPS from continuing operations in Key Details table to -$0.39, from -$1.56
Overview
Oncology firm's Q4 revenue missed analyst expectations
LOQTORZI product sales more than doubled yr/yr, driven by higher patient demand
Company reduced debt by 90% from $480 mln to $38.8 mln over 2024-2025
Outlook
Coherus anticipates initial data readouts for tagmokitug studies in mid-2026
Company plans to begin mCRPC study with pasritamig in 2H 2026
Coherus expects first data from casdozokitug Phase 2 trial in mid-2026
Result Drivers
LOQTORZI SALES GROWTH - LOQTORZI net revenue more than doubled to $40.8 mln in 2025 from $19.1 mln in 2024, driven by higher patient demand and longer treatment durations
Company press release: ID:nGNXc55pb6
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q4 Sales | Miss | $12.75 mln | $13.94 mln (6 Analysts) |
Q4 EPS From Contops | -$0.39 | ||
Q4 Adjusted Net Income From Contops | Miss | -$40.42 mln | -$35.15 mln (5 Analysts) |
Q4 Net Income | -$37.64 mln | ||
Q4 Operating Income | -$45.88 mln |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for Coherus Oncology Inc is $6.00, about 229.7% above its March 6 closing price of $1.82
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)